Unlike generics, which are the exact chemical copies of a brand-name drug, biosimilars have large and often complex proteins that are made in living cells, and tiny differences can play havoc with the product. It may take years for the FDA to create an approval process.
Continue reading How to Approve ‘Biosimilar’ Drugs? The FDA Has to Figure That Out
How to Approve ‘Biosimilar’ Drugs? The FDA Has to Figure That Out originally appeared on DailyFinance on Wed, 03 Nov 2010 17:20:00.
Filed Under: Health Care, Johnson & Johnson, Pfizer, Merck, Amgen